Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Wegovy's approval by China's NMPA targets individuals with a BMI of 30+ with related health issues; initial supply will be ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

Not only is Wegovy extremely effective (people lose about 15% of their body weight in a year), it also appears to have many ...

Popular semaglutide-based drugs used for weight loss may reduce chronic and acute pain, which could make them a promising ...